We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-11.95%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$545M
AUM Growth
-$226M
Cap. Flow
-$100M
Cap. Flow %
-18.35%
Top 10 Hldgs %
72.8%
Holding
51
New
4
Increased
7
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$33.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$29.4M
3
APLS
Apellis Pharmaceuticals
APLS
+$27.4M
4
BCYC
Bicycle Therapeutics
BCYC
+$15.8M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$13.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$30.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$28.8M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$21.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$20.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
26
Tyra Biosciences
TYRA
$1.91B
$1.19M 0.22%
166,526
-86,200
-34% -$686K
LIAN
27
DELISTED
LianBio American Depositary Shares
LIAN
$852K 0.16%
394,486
-18,351
-4% -$62.3K
LONA
28
LeonaBio Inc
LONA
$65.9M
$671K 0.12%
22,000
-49,729
-69% -$4.56M
VIGL
29
DELISTED
Vigil Neuroscience
VIGL
$530K 0.1%
205,595
– –
PYXS icon
30
Pyxis Oncology
PYXS
$187M
$525K 0.1%
220,434
-66,218
-23% -$176K
NUVL
31
DELISTED
Nuvalent
NUVL
$460K 0.08%
33,887
-100,763
-75% -$1.07M
NUVB.WS
32
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$19K ﹤0.01%
66,666
– –
ANAB icon
33
AnaptysBio
ANAB
$1.62B
– –
-300,000
Closed -$7.42M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.8B
– –
-175,000
Closed -$20.5M
BMEA icon
35
Biomea Fusion
BMEA
$94M
– –
-200,000
Closed -$892K
CGEM icon
36
Cullinan Oncology
CGEM
$1.09B
– –
-200,000
Closed -$2.09M
COGT icon
37
Cogent Biosciences
COGT
$6.98B
– –
-150,000
Closed -$1.12M
IMA
38
ImageneBio Inc
IMA
$64.3M
– –
-14,857
Closed -$1.09M
IOVA icon
39
Iovance Biotherapeutics
IOVA
$2.23B
– –
-1,000,000
Closed -$16.6M
SRRK icon
40
Scholar Rock
SRRK
$5.96B
– –
-675,000
Closed -$8.7M
VERA icon
41
Vera Therapeutics
VERA
$2.57B
– –
-385,000
Closed -$9.04M
VERV
42
DELISTED
Verve Therapeutics
VERV
– –
-96,912
Closed -$2.21M
VRNA
43
DELISTED
Verona Pharma
VRNA
– –
-300,000
Closed -$1.5M
VTGN icon
44
VistaGen Therapeutics
VTGN
$9.24M
– –
-33,333
Closed -$1.24M
OMGA
45
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
– –
-12,986
Closed -$81K
RAIN
46
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-134,194
Closed -$680K
MRTX
47
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-350,000
Closed -$28.8M
SLGC
48
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-100,000
Closed -$802K
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,800,000
Closed -$30.3M
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-1,400,000
Closed -$9.51M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2022 Portfolio in Review

As of Q2 2022, Logos Global Management held 51 positions worth $545M, down 29% from $771M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Logos Global Management withdrew a net $100M in Q2 2022, closing 19 positions and reducing 16 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $43.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $27.9M.

  • Logos Global Management's largest Q2 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 350,000 shares worth $27.9M.
  • Logos Global Management added most to Apellis Pharmaceuticals in Q2 2022, an estimated $27.4M increase.
  • Logos Global Management's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $21.8M.
  • Logos Global Management fully exited Global Blood Therapeutics, Inc. in Q2 2022, selling an estimated $43.3M.
  • Logos Global Management's ten largest holdings make up 73% of its $545M portfolio in Q2 2022.
  • Logos Global Management opened 4 new positions and closed 19 in Q2 2022.
  • Logos Global Management's portfolio value fell 29% quarter-over-quarter to $545M.

Based on Logos Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.